WCE 2018: Mayo Clinic Pilot Experience with Rezūm Prostate Ablation

Paris, France (UroToday.com) Water vapor thermal therapy is a new minimally invasive technique for treating benign prostatic hyperplasia (BPH). Moreso, the Rezūm ablative system has recently been deemed appropriate for clinical use. In this study, the authors sought to investigate the efficacy and overall utility of the Rezūm Ablation system.

This study was a retrospective study of 150 patients who received treatment for BPH in a tertiary care center between July 2017 and March 2018. Treatments were done either under standard prostate block or under sedation. Patients with larger prostates received “stacked” treatments to the lateral lobes.

The authors reported a significant improvement in AUA symptom score, peak flow, and post-void residual volume using the Rezūm ablative platform. Dr. Yang indicated that the Rezūm system appeared to be effective and safe despite the novelty of the technology. Furthermore, the authors reported that 84% of the men requiring catheters were free from their catheter by their last follow-up visit. Also of note, there was a relatively high rate of urinary tract infections within this cohort.

In sum, the authors indicated that although their findings were thought-provoking, a study with more power is required to completely and accurately assess the efficacy of Rezūm’s ablative capabilities.

Presented by David Yang, MD
Co-Authors: Ross A Avant, Ajay Gopalakrishna, Sevann Helo, Manaf Alom, Tobias S Kohler
Author Affiliation: Mayo Clinic, Rochester, MN USA
Written by: Mitchell O’Leary, Department of Urology, University of California-Irvine) medical writer for UroToday.com at the 36th World Congress of Endourology (WCE) and SWL - September 20-23, 2018 Paris, France

Login